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AIMS AND OBJECTIVES
1. To study the side effects & complications following intravesical instillation of BCG.
2. To study the tolerability following administration of intravesical BCG.
MATERIALS AND METHODS
Patients
The  patients  of  suspected  ca  bladder  coming  to  our  institute  from  March  2005  to 
September 2007 were evaluated. Thorough history and physical examination was done & also 
detailed history about addictions and co morbidities was taken.
All patients underwent complete transurethral resection of the tumor (in one or more 
acts), which established the tumor size, histological type, grade, stage, and absence of muscle 
invasion. Patients who had histologically proven superficial transitional cell carcinoma stage 
Ta and T1 and were eligible for intravesical BCG instillation treatment. 
Tumors were staged according to the TNM classification of The Union
Internationale Contre le Cancer and tumor grade by WHO grading was done. 
Intravesical BCG instillations were offered to all willing patients.
Methods
The protocol  of  immunoprophylaxis  with  BCG consisted  of  6  weekly  +  6  monthly 
instillations.  Instillations  began  2-3  weeks  after  transurethral  resection  and  after  obtaining 
histological  documentation of  papillary  transitional  cell  carcinoma for  each patient.  Before 
proceeding  with  instillation  all  patients  were  examined and symptoms were  noted  for  any 
adverse effects and also urine routine testing was done& therapy delivered only if patient found 
to be fit for the therapy..
Therapy  consisted  of  bladder  instillations  of  120  mg  of  "1331  strain”  of  BCG 
(‘UROVAC’ manufactured by Govt of India, Chennai), suspended in 100 mL of saline.
Instillations were performed after the bladder was catheterized and completely drained. 
We ensured not to insert any air or cause trauma or bleeding during catheterization.
The patients were instructed to lie down for 2 h and change position every 15 min to 
allow maximal contact of the suspension with the bladder mucosa. Patients were instructed to 
hold the urine for as long as longer minimum 2 hours. 
Following instillation patients were instructed to report any side effects or any untoward 
adverse  reactions  immediately.  Patients  presenting were  evaluated and managed as  per  the 
requirements. 
Follow-up consisted of cystoscopic examinations every 3 months, urine cytology, and 
mucosal biopsies of all overt or suspicious areas in the bladder in the first year and at the 6-
month intervals in the second year and later. 
INTRODUCTION
The Ca Bladder is one of the important tumors of the genitourinary cancers and usually 
affects the people all around the globe. Broadly urinary bladder cancers can be divided into 
superficial, muscle invasive and metastatic cancers. Of which superficial cancers constitute the 
majority  of  cases.  Superficial  bladder  cancers  are  the  tumors  confined  to  the  mucosa  and 
submucosa (Ta, Tis & T1). This is a heterogeneous disease with variable natural history. 
At one end of the spectrum are low grade tumors (Ta) with low potential for progression 
& rarely represent a threat to the patient, while at the other end are the high grade (T1) tumors 
with high malignant potential with significant progression and death.
Although  thorough  endoscopic  tumor  resection  remains  the  principal  treatment, 
intravesical agents have become an important in the subgroup of tumors that are at risk of 
progression.  Intravesical  Bacillus  Calmette-Guerin,  is  effective  treatment  in  preventing 
recurrences & delaying progression in superficial bladder cancer. It  has been in use since the 
1980's, and is the most proven and effective form of immunotherapy. Though therapy with 
BCG is generally safe, it is not completely, without side effects. 
This study was done to know the various side effects, outcomes and tolerability of the 
therapy. 

REVIEW OF LITERATURE
TCC of the bladder can be divided into 2 categories: superficial tumors and muscle-
invasive  tumors.  Superficial  TCC  tumors  are  those  that  have  not  invaded  the  muscularis 
propria, regardless of grade. They include papillary lesions confined to the urothelium that do 
not penetrate the basement membrane (Ta), tumors with invasion into the lamina propria (T1), 
and carcinoma in situ (CIS). At the time of diagnosis, 64% to 80% of cases are superficial; of 
those, 70% are stage Ta and 30% are stage T1.1 Despite complete resection, recurrence rates 
are 66% at 5 years and 88% at 15 years.2 Progression from superficial bladder cancer to deep 
muscle invasion occurs in 15% of patients.3
EPIDEMIOLOGY  
Approximately 80 percent of cases of bladder cancer are diagnosed in people over the 
age of 60.
Globally, the incidence of bladder cancer varies approximately 10-fold, with Western 
Europe and North America having the highest and Eastern Europe and Asian countries the 
lowest rates.4 In some high incidence regions, bladder cancer is associated with specific disease 
states or toxin exposures (Balkan countries, Taiwan)
In United States, Cancer of the urinary bladder is the fourth most common cancer in 
men and the ninth in women & it is the second most prevalent cancer in men 60 years of age or 
older.  In  the  United  States  in  2007  an  estimated  67,160  new cases  of  bladder  cancer  are 
expected to be diagnosed (approximately 50,040 men and 17,120 women),  with an overall 
lifetime risk of developing bladder cancer of approximately 1 in 28.5, 6
South East Asia  No uniform data exists however in  Southeast Asia; the incidence in 
2002 was 2.7 per 100,000 in males and 0.8 per 100,000 in females, making it the ninth most 
common cancer in men.7 
In India and in MMTR (Madras Metropolitan registry) In  India  the  reported 
incidence  of  Ca  bladder  is  1.71  per  100,  000  population.  In  Chennai  MMTR the  overall 
incidence is 1.85 per 100,000 population.8
Gender – Male to female ratios are 3 to 4:1 in the United States as a whole, 7:1 in Italy, 
and 10:1 among American Indians.9, 10  In India the incidence in males being 2.72 and females 
as 0.7 per 100,000 population. While in Chennai MMTR it is 2.9 & 0.8 in males and females 
respectively.8 
Racial and ethnic variations  Non-Hispanic white males are at highest  risk,  while 
the observed incidence in African-Americans and Latinos is approximately one-half of that 
number. 11, 12 Bladder cancer rates in Asian populations in the United States, including Chinese 
and Japanese-Americans, are about 40 percent those of non-Hispanic whites, while incidence 
rates for American Indians are about one-eighth that numbers. A possible explanation for these 
disparities is variations in acetylator phenotypes in different racial/ethnic groups 12 
ETIOLOGY AND RISK FACTORS 
Many of the aetiological factors for the development of bladder tumours are known. 
Environmental  exposures  are  thought  to  account  for  most  cases  of  bladder  cancer  and 
occupational exposures remain a significant risk factor for bladder cancer. 
The characteristic feature of urothelial carcinomas of both the urinary bladder and the 
upper urinary tract is multifocality ("field cancerization" hypothesis”).13
However,  in  the majority  of  cases,  multifocal  urothelial  carcinomas are monoclonal. 
This supports their presumed origin from a single genetically altered cell, which then spreads 
through the urothelium via intraluminal seeding or intraepithelial migration.14, 15 This is referred 
to as the monoclonality hypothesis.
Chemical carcinogens — 
Aromatic  amines,  aniline-containing  dyes  and  arylamines,  such  as  2-naphthylamine, 
benzidine and 4-aminobiphenyl rubber, amides and azodyes have been implicated as bladder 
carcinogens.16
Occupational  and  environmental  exposures — aluminum,  dye,  paint,  petroleum, 
rubber, and textile industries are estimated to account for up to 20 percent of all bladder cancer 
cases.17, 18 Other occupations at an excess risk has been described in hairdressers and barbers, 
which is thought related to exposure to hair dyes.19, 20 
Cigarette smoking —The association between cigarette  smoking and bladder  cancer 
was  first  established  in  195621,  and  multiple  studies  have  demonstrated  a  two to  threefold 
increased risk in smokers compared to nonsmokers.22, 23, 24 
Drinking  water — the  by-products  of  water  chlorination  and  the  concentration  of 
arsenic in drinking water have been associated with an elevated risk of bladder cancer. Arsenic, 
both ingestion and inhalation of arsenic have been linked to the development of lung, skin, and 
bladder cancers.25, 26 
Fluid  consumption — is  inversely  associated  with  urothelial  exposure  to  potential 
carcinogens.27
Analgesic abuse — particularly phenacetin has been linked to chronic kidney disease 
and cancers of the kidney, renal pelvis and bladder.28
Artificial sweeteners — (e.g.,  saccharin, cyclamates) At least 13 case-control studies 
have failed to convincingly demonstrate an increased risk of bladder cancer in people exposed 
to saccharin or cyclamates.29 However, subgroup analysis in some reports suggests an increased 
risk of bladder cancer formation in non-smoking women, a group with an overall low risk for 
this disease.
Coffee consumption — the results of epidemiologic studies have been inconsistent, and 
those  that  do  show  a  weak  association  probably  reflects  the  confounding  influence  of 
smoking.30 Although the best available data do not support a clinically important association 
between the regular use of coffee and bladder cancer, the consumption of ten or more cups per 
day is suspected to be associated with a slightly increased risk, independent of the influence of 
smoking 71
Genetic  factors — the  Swedish  Cancer  Registry  identified  families  with  a  parental-
offspring  bladder  cancer  concordant  history.  These  families  exhibited  a  high  sibling  to 
offspring risk and a greater prevalence within female offspring, suggesting the possibility of an 
X chromosome-linked gene defect.32 
A  study  from  MD  Anderson  evaluated  the  impact  of  smoking  and  bladder  cancer 
development among individuals with a familial history of bladder cancer. A five fold increased 
risk of developing bladder cancer was observed among those individuals with both a family 
history of bladder cancer and a prior history of smoking. This risk increased to nearly sevenfold 
when the family member was diagnosed with bladder cancer at younger than 65 years of age. 33 
Chronic cystitis — Individuals with recurrent or chronic bladder infections and those 
who have  an  ongoing source  of  bladder  inflammation  (eg,  prolonged indwelling  catheters, 
bladder  calculi,  gonorrhea)  have  a  higher  risk  of  bladder  cancer  compared  to  the  general 
population.34, 35 The frequency of SCC as opposed to TCC is higher in this setting.
Schistosomiasis — Infection  with  S.  haematobium,  also known as  bilharzial  bladder 
disease, has been linked to hyperplasia, metaplasia, dysplasia and overt invasive carcinoma in 
the bladder.36
Treatment-related carcinogenesis 
  Radiation — an  increased  risk  for  developing  secondary  bladder  cancer  has  been 
associated with pelvic radiation for cervical, ovarian, and prostate cancers.37-40 The relative risk 
ranges from 1.5- to fourfold, and is proportional to dose. Radiation-related bladder cancer has a 
relatively  short  latency  period  (five  to  ten  years),  and  is  characteristically  high-grade  and 
muscle-invasive at diagnosis.41-43
  Chemotherapy — Patients  treated  with  cyclophosphamide  as  an  antitumor  or 
immunosuppressive  agent have up to a  nine-fold increased risk of  bladder  cancer,  and the 
latency period is generally short (less than 10 years). 44 - 47
PATHOLOGY AND GRADING OF TUMORS
The cells  comprising  the  lining  of  the  urinary  tract  are  transitional  cells.  The  most 
common histology is
• Transitional cell cancers (TCCs), > 90%
• Squamous cell cancers (SCCs), 3 to 5%
• Adenocarcinomas, 0.5 to 2 %
• Small cell carcinomas, <1% 
HISTOLOGIC GRADE — Bladder  tumors  are  now classified  as  either  low or  high 
grade. This replaces the previous system of classification in which tumors were designated as 
low (G1), intermediate (G2), or high (G3) grade. The histologic grade varies in noninvasive 
tumors, while almost all invasive neoplasms (tumor stage T1) are high grade. The histologic 
grade is based upon the degree of resemblance to the normal tissue architecture. The normal 
urothelium has a thickness of less than five to seven cell layers, normal polarity of nuclei, and 
no pleomorphism.
WHO/ ISUP grading
In  2004,  members  of  the  WHO  and  International  Society  of  Urologic  Pathologists 
published and recommended a revised consensus classification for papillary neoplasms.48 A 
new  category  of  papillary  urothelial  neoplasm  of  low  malignant  potential  was  created  to 
describe lesions with an increased number of urothelial layers when compared with papilloma 
but  without  cytologic  features  of  malignancy.48 Although  they  have  a  negligible  risk  for 
progression, they are not completely benign and still have a tendency to recur.
WHO/ International Society of Urologic Pathologists2004:
Classification of Nonmuscle Invasive Urothelial Neoplasia48
Hyperplasia (flat and papillary)
Reactive atypia
Atypia of unknown significance
Urothelial dysplasia
Urothelial carcinoma in situ
Urothelial papilloma
Papillary urothelial neoplasm of low malignant potential
Nonmuscle invasive low-grade papillary urothelial carcinoma
Nonmuscle invasive high-grade papillary urothelial carcinoma
CLINICAL PRESENTATION — 
The diagnosis of bladder cancer is often delayed due to the similarity of symptoms to 
those of benign disorders (eg, urinary tract infection, interstitial cystitis,  prostatitis,  and the 
passage of renal calculi). Furthermore, symptoms are often intermittent. The symptoms also 
depends on the occurrence of the three clinical presentations of bladder cancer (ie, superficial, 
invasive, and metastatic).
Hematuria — The most common presenting symptom is hematuria, which is typically 
intermittent, gross, painless, and present throughout micturition. 
The degree of  blood in the urine  is  not predictive of the probability  of  cancer.  The 
prevalence of asymptomatic hematuria in the general population is estimated at 2.5 percent.49 
Microscopic hematuria is present in up to one-fifth of the general population and predominant 
cause is usually benign. In one population-based study, asymptomatic microscopic hematuria 
was present in 13 percent of the population, but attributed to urothelial cancer in only 0.4 
percent.50
Pain — Pain usually indicates locally advanced or metastatic tumor. Its distribution is 
related to the size and location of the primary tumor or its metastases. Flank pain may result 
when a  tumor  obstructs  the  ureter  at  any  level  (bladder,  ureter  or  renal  pelvis).  Although 
usually a sign of a  muscle-invasive disease,  large superficial  tumors located at  the ureteral 
orifice may also cause symptomatic obstruction. The pain is similar to that experienced with 
the passage of urinary stones, and may or may not be associated with hematuria. Suprapubic 
pain is usually a sign of a locally advanced tumor that is either directly invading the perivesical 
soft  tissues  and  nerves,  or  obstructing  the  bladder  outlet  and  causing  urinary  retention. 
Hypogastric and perineal pain are ominous signs of advanced disease invading the obturator 
fossa, presacral nerves, or the urogenital diaphragm. Bone pain may indicate the presence of 
metastases. 
Voiding  symptoms — Irritative  voiding  symptoms  (e.g.,  daytime  and/or  nocturnal 
frequency, urgency, dysuria, or urge incontinence) occur in approximately one-third of patients 
with bladder cancer. Voiding symptoms are most common in patients with carcinoma in situ, 
and  may  result  from  a  functional  decrease  in  the  bladder  capacity,  detrusor  overactivity, 
invasion of the trigone, or obstruction of the bladder neck or urethra. In particular, the complex 
of dysuria, frequency, and urgency is highly suggestive of bladder CIS. Obstructive voiding 
symptoms are less common, and may be due to tumor location at the bladder neck or prostatic 
urethra.  Symptoms  include  straining,  an  intermittent  stream,  nocturia,  decreased  force  of 
stream, and a feeling of incomplete voiding. On occasion, gross hematuria may result in "clot 
retention". 
Constitutional  symptoms — Symptoms  such  as  fatigue,  weight  loss,  anorexia,  and 
failure  to  thrive  are  usually  signs  of  advanced  or  metastatic  disease  and  denote  a  poor 
prognosis.
DIAGNOSTIC APPROACH 
The goal of the diagnostic evaluation is to determine the diagnosis, site, and extent of 
cancer, and the presence or absence of muscle-invasive disease.
The  presence  of  otherwise  unexplained  hematuria  denotes  an  urothelial  cancer  in 
individuals over the age of 40 until proven otherwise and requires a full urologic evaluation of 
the entire urinary tract. 
Recommendations for assessment of TaT1 bladder tumours 
(EAU, 2006)51: 
The  European  Association  of  Urology  recommends  the  following  investigations  for 
assessment of superficial bladder cancers.
• Urine analysis (microscopic and gross examination)
• Urine cytology
• Renal and bladder USG and/or IVU in selected cases (grade 3 tumours)
• Cystoscopy with description of the tumour: site, appearance 
• TUR in one piece for small tumours, including a part from the underlying bladder wall
• TUR in fractions (including muscle tissue) for larger tumours
• Selected biopsies of abnormal-looking urothelium
• Biopsy of the prostatic urethra in case of bladder neck tumour, or suspicion of CIS.
Urine analysis – 
Urine color can be affected by its concentration, ingestion of certain foods or drugs, and 
the presence of bacteria. 
Urinary pigments that can mimic hematuria include 
• Betalaine contained in beets (beeturia) 
• Phenazopyridine, a urinary analgesic 
• Vegetable dyes 
• Urates 
• Myoglobin 
• Serratia marcescens 
• Phenolphthalein, component of many over-the-counter laxatives
Microhematuria is usually not considered significant unless there are more than 3 RBCs 
per HPF. RBC morphology may also suggest the etiology of the hematuria; cells of glomerular 
origin  are  often  dysmorphic  or  formed  in  casts,  indicating  intrinsic  renal  disease,  while 
isomorphic RBCs are more likely from an extrinsic source such as calculi, tumor, obstruction, 
or infection. 
Urine cytology — the sensitivity of urine cytology is greatest for CIS, about 90 percent. 
In contrast, sensitivity for upper tract TCC is limited; the reported false negative rate overall is 
65 percent, and may be as high as 96 percent for low-grade tumors.52, 53
Urine flow cytometry — the role of flow cytometry in screening patients for urothelial 
malignancies  is  unclear.  Evaluation  of  abnormal  tumor  DNA ploidy  (aneuploidy)  by  flow 
cytometry  may  be  more  accurate  than  cytology  for  detecting  the  presence  or  absence  of 
exfoliated malignant cells. Compared to cytology, which is labor intensive, flow cytometry is 
an automated screening procedure. One drawback is that a catheterized specimen rather than 
voided urine is required.
Urine  immunocytochemistry  and proteomics  assays — the  limitations  of  cytology 
and the invasiveness of cystoscopy for detecting bladder cancer have generated interest in other 
non-invasive  diagnostic  tools,  such  as  urine  immunocytochemistry  (ImmunoCyt  test)  and 
proteomics assays for the nuclear matrix protein NMP22 (NMP22 BladderChek test).54, 55 
These assays are most promising as tools to improve the detection rate for low-grade 
tumors. Compared to cytology, the ImmunoCyt test appears to be more sensitive for low-grade 
tumors.56 Although it is more sensitive for detecting low-grade cancer than urine cytology, the 
ImmunoCyt test is not sensitive enough to replace cystoscopic examination. Urine cytology is a 
better test for detecting high-grade disease. 
NMP22 proteomics assay — Proteomics refers to the analysis of protein expression in 
tissues, serum, and other biologic samples in order to identify and/or characterize malignant 
tumors  on  the  basis  of  unique  protein  expression  patterns.  The  NMP BladderChek test  is 
approved in the United States for diagnosis of bladder cancer.
Other urinary biomarkers - Intense evaluation of multiple other urinary biomarkers 
including DNA ploidy  and qualitative  fluorescence image analysis,  molecular  cytogenetics, 
telomerase expression, tumor associated intracellular or secreted products, oncogene mutations, 
micro satellite alterations, and markers of apoptosis is underway.57-61  Several are approved in 
the United States (eg, BTA Stat, BTA TRAK, UroVysion tests) for the detection of recurrent 
bladder  tumors,  but  none  is  approved  for  widespread  screening,  initial  diagnosis,  or  risk 
assessment62 None of these tests has shown sufficient diagnostic reliability to eliminate the 
need for cystoscopy for either primary or recurrent bladder tumors63 
Radiographic imaging (including the upper tract)
The purpose of the radiographic evaluation is to identify the tumor location, and assess 
the possibility of multifocal disease.
• USG KUB
• CT scan of abdomen & pelvis
• Intravenous pyelography
Ultrasound — USG is not very useful for the diagnosis or staging of bladder cancer. It 
can confirm a soft tissue mass, but usually cannot determine depth of invasion, the presence of 
extravesical extension, or nodal status. However, it is useful in evaluating the upper tracts for 
renal parenchymal disease, hydronephrosis, and to differentiate a non-radiopaque stone from a 
soft tissue mass by differences in echogenicity.64
IVP — IVP is more sensitive for detection of small lesions of the ureter or renal pelvis, 
while CT scan or renal ultrasound (US) are better tests for the evaluation of renal parenchymal 
disease. 
The  cystogram phase  of  the  IVP detects  60  to  85  percent  of  large  bladder  tumors; 
however, smaller tumors may be missed. The classic urographic findings of an upper tract TCC 
is a meniscus-shaped ureteral filling defect known as the "goblet" or "Bergmann" sign, and the 
"stipple sign" produced by contrast being trapped in the fronds of a papillary tumor.
About 50 percent of patients with a filling defect either in the renal pelvis or ureter will 
have associated hydronephrosis, hydroureter, or nonvisualization of the kidney secondary to 
obstruction.  Invasive  bladder  tumors  may  cause  distal  ureteral  obstruction  and  secondary 
hydronephrosis.
 
CT  scan — IVPs  are  gradually  being  replaced  by  helical  CT  scanning.  CT  may 
demonstrate  extravesical  extension,  nodal  involvement  in  the  pelvis  or  retroperitoneum, 
visceral,  pulmonary or osseous metastasis,  and upper tract  function,  tumor involvement,  or 
obstruction. Although CT provides better visualization of tumors than US, it may also miss 
tumors <1 cm in size, particularly those in the bladder trigone or dome, and cannot differentiate 
depth of bladder wall invasion (ie. mucosal versus lamina propria or muscularis propria).  65 
Although a thickened bladder wall on CT suggests the presence of muscle invasive disease, 
tissue is required for diagnosis.
CT is about 80 percent accurate in differentiating locally advanced tumors involving 
extravesical  adipose  tissue  or  surrounding structures  from less  invasive  tumors.  It  may  be 
difficult to distinguish inflammatory or iatrogenic edematous changes from true extravesical 
tumor extension if CT is performed after a transurethral resection.
The sensitivity of CT for identification of nodal involvement is  relatively low (false 
negative rate 68 percent, false positive rate 16 percent), and requires a needle or excisional 
biopsy for confirmation.65
Cystoscopy –   Cystoscopy  forms  the  mainstay  of  diagnosis  and  staging  of  bladder 
cancer.  The  bladder  is  inspected  visually,  and  a  detailed  description  of  the  size,  number, 
location, and growth pattern (papillary or solid) of all lesions is recorded. The status of the 
uninvolved mucosa is also noted.
TURBT –  Biopsy specimens are taken from visible tumors, or the tumors are resected 
transurethrally  in stages to determine the histologic subtype and depth of invasion into the 
submucosa  and  muscle  layers  of  the  bladder.  For  patients  undergoing  repeat  diagnostic 
cystoscopy  after  a  prior  TURBT,  repeat  biopsy  should  be  obtained  from  areas  that  were 
previously resected, even if they appear clinically uninvolved, since about one-third of areas 
involved with prior superficial disease will be upstaged by the detection of muscle invasive 
disease.66
Completion of the staging workup –   Once the diagnosis of cancer is made, other 
imaging studies may be appropriate to evaluate for extravesical extension and other sites of 
disease (eg, metastatic lesions). The decision whether or not to perform additional diagnostic 
studies is based upon the results of the physical and bimanual examination, cystoscopy and the 
histologic/cytologic evaluation. 
  Chest  X ray — Chest  x  rays  are  used  as  an  initial  screening  tool  and  for  periodic 
monitoring in patients at risk for pulmonary metastasis, although they are insensitive for lesions 
<1 cm. Metastatic lesions are typically non-calcified soft tissue densities. If the chest film is 
suspicious, a chest CT is warranted.
  MRI — Magnetic resonance imaging (MRI) is as reliable as CT for staging of invasive 
or  locally  advanced disease,  and  may better  evaluate  tumors  at  the  base  and dome of  the 
bladder. Contrast (gadolinium-enhanced) MRI may be superior to CT particularly in detecting 
superficial  and  multiple  tumors,  extravesical  tumor  extension,  and  surrounding  organ 
invasion.67-69
  Transvesical needle biopsy — CT-guided transabdominal fine needle aspirate biopsy of 
the bladder wall may be potentially useful for staging, since it permits full thickness transmural 
evaluation of bladder masses.70 
  Bone scan — Radionuclide bone scans to assess the presence of bone metastasis are 
recommended only in patients with invasive or locally advanced tumors and either skeletal 
symptoms or unexplained elevations in serum alkaline phosphatase. Plain radiographs, CT, or 
MRI of suspicious areas may be necessary to confirm a metastasis. Bone biopsy should be 
performed to document metastatic disease if necessary
CLINICAL  STAGING — The  most  commonly  used  staging  system  is  the  TNM 
(tumor, node, metastasis) system, developed from pathologic studies of cystectomy specimens, 
in which the association between depth of invasion and clinical course was first identified. 71
2002 TNM classification of urinary bladder cancer71
MANAGEMENT 
For patients with superficial bladder cancer, the initial treatment generally is a complete 
transurethral resection of all visible bladder tumors (TURBT) which is followed by adjuvant 
treatment. The choice between chemotherapy and immunotherapy largely depends on the risk 
that  needs  to  be  reduced,  recurrence  or  progression.  Adjuvant  chemotherapy  bladder 
instillations  are  effective  in  preventing  recurrence  in  low-grade  tumours.  In  high-grade 
tumours,  bacillus Calmette-Guerin (BCG) therapy has proven to be superior  to intravesical 
chemotherapy. A brief overview of treatment plan is as per the algorithm below.
Two meta-analyses demonstrated that BCG therapy prevents, or at least delays, tumour 
progression72, 73 (level of evidence: 1a).
History: Development of BCG74
In 1904, Nocard isolated Mycobacterium bovis.
In 1908, Calmette and Guérin, obtained a special avirulent special M. bovis strain, after 
231 subcultures over a period of 13 years, which was named Bacillus of Calmette and Guérin, 
or BCG. Storage was a problem at that time so it was necessary to subculture, which led to 
genetic variability and the emergence of various sub strains. 
In  1929,  Pearl  observed  that  patients  who  suffered  from  tuberculosis  had  lower 
frequency of cancer, and BCG as a cancer therapy was first suggested, but it was only in the 
1960s that it was taken up.
In 1969, Mathe et al showed promising results in treating lymphoblastic leukaemia with 
BCG. 
In  1974,  Zbar  and Rapp formulated  conditions  necessary  for  antitumour  effect  with 
BCG:
• Ability to develop an immune response to mycobacteria antigens;
• Adequate number of living bacilli;
• Close contact between BCG and tumour cells;
• The tumour burden must be small.
In  1976, Morales et al noted that all the conditions were present in superficial bladder 
cancer and was able to show a decrease in recurrence rate in the nine patients he initially 
treated. After Lamm et al confirmed these findings in a larger study, BCG has been widely 
used in the treatment of superficial bladder cancer.
Indications for Intravesical BCG Therapy 51
The 3 main objectives that guide the use of intravesical therapy of superficial bladder 
cancer are: 
1. to treat existing tumor or carcinoma in situ, 
2. to prevent recurrence in a bladder rendered free of tumor, and 
3. to prevent progression of disease. 
Prior to initiating intravesical therapy, an attempt to minimize the extent of disease by 
resection and fulguration should be made, since a low tumor burden increases the chances of 
therapeutic success.
Although BCG is considered to be a very effective treatment, consensus exists that not 
every patient with superficial bladder cancer should be treated with BCG due to its increased 
risk of toxicity. 
BCG can delay or prevent progression to muscle-invasive disease. The use of BCG will 
not alter the natural course of the disease in low-risk patients and may be considered to be over-
treatment for this category.
Ultimately, the choice of treatment will depend upon the patient’s risk of recurrence and 
progression. 
In  patients  with  high-risk  tumours  for  whom  a  cystectomy  is  not  carried  out,  no 
controversy  exists  about  how to  treat  these  patients.  In  multiple  T1G2 tumours,  Ta-T1G3 
tumours with or without CIS, and CIS alone, where 15% or more of the patients will progress, 
the advantages of intravesical BCG are more pronounced than in intermediate-risk patients, 
who are at a lower risk of progression (level of evidence: 1). 
The treatment of the remaining intermediate-risk tumours (multifocal T1G1, TaG2 and 
single  T1G2  tumours)  is  more  controversial.  It  consists  of  complete  TUR  followed  by 
intravesical chemotherapy or intravesical BCG. The major issue in intermediate-risk tumours is 
to prevent recurrence and progression, of which recurrence is by far the most likely. Millan-
Rodriguez  et  al.  found  that,  while  tumour  will  recur  in  about  45% of  these  patients,  the 
likelihood of progression to muscle-invasive disease is low in these patients at approximately 
1.8%.
Although  BCG  is  superior  to  chemotherapy  in  preventing  recurrences,  controversy 
existed until recently as to whether BCG could delay or prevent progression to muscle-invasive 
disease. A meta-analysis carried out by the EORTC has provided a clinically relevant answer to 
this question (level of evidence: 1). A total of 24 randomized trials were identified with follow-
up information on progression for 4,863 patients. A total of 3,967 (81.6%) patients had only 
papillary tumours and 896 (18.4%) had primary or concomitant CIS. 
Five different BCG strains were used, and in 20 out of the 24 trials some form of BCG 
maintenance was used. In four trials only, a 6-week induction course was used. Based on a 
median follow-up of 2.5 years and a maximum of 15 years, 260 out of 2,658 patients (9.8%) on 
BCG progressed compared to 304 out of 2,205 (13.8%) in the control groups (TUR alone, TUR 
plus  intravesical  chemotherapy,  or  TUR  plus  another  immunotherapy).  This  result  is  a 
reduction of 27% in the risk of progression with BCG treatment (p =0.0001). The size of the 
reduction is similar in patients with Ta,T1 papillary tumours and in those with CIS.
Mechanism of action74, 75
The exact antitumour mechanism of BCG is not clear but it is known that a complex 
cascade of immuno modulating processes is involved. The importance of an intact immune 
system in the antitumour activity of BCG was first demonstrated by Ratliff and colleagues.75 T 
lymphocytes and cell mediated immunity are important in the immune response to BCG.
After  intravesical  instillation,  live  mycobacteria  attach  to  the  urothelial  lining.  This 
binding is facilitated by fibronectin, which is a component of the extracellular matrix and BCG 
undergoes endocytosis. 
The contact between BCG and the epithelium is important as BCG induced antitumour 
activity  is  localized  to  the  site  of  contact.76,  77 This  process  leaves  bacterial  cell  surface 
glycoprotein attached to the epithelial cell membrane and this interaction of BCG leads to the 
activation of urothelial and antigen presenting cells (APC). The APC include macrophages, B 
lymphocytes,  dendritic  cells  and  Langerhans  cells.  The  APC process  and  present  antigens 
which are then linked to major histocompatibility (MHC) class II molecules for recognition by 
T helper cells.
Intravesical BCG therapy has been noted to induce local production of various cytokines 
including interleukin- 1 (IL-1), IL-2, IL-5, IL-6, IL-8, IL-10, IL-12, IL-18, interferon gamma 
(IFN-γ) and tumour necrosis factor alpha (TNF-α).52 
These  cytokines  are  known  to  be  involved  in  the  initiation  or  maintenance  of  the 
inflammatory process.78
It  is  thought  that  the  initial  production  of  cytokines,  after  BCG  instillation,  is  by 
macrophages and urothelial cells and further production is by activated T cells.78 The cytokines 
produced after intravesical BCG have been identified in the urine of patients. The majority of 
the cytokines produced are mainly the T helper type 1 (TH1) cytokines like IFN-γ, IL-2 and 
IL-12. It has also been shown that the production of cytokines associated with TH2, like IL-4, 
are decreased and patients who have a high level of TH2-associated cytokines are more likely 
to have BCG failure.79, 80 
A few studies have shown that cytokine levels  can be used to predict  the long-term 
response to BCG treatment with higher levels indicating a lower recurrence rate and a longer 
recurrence-free interval.
The main mechanism by which BCG stimulates the immune system to overcome the 
tumour is by playing a role, either directly or indirectly, in the production of effector cells. 
These include the stimulation of cytotoxic T lymphocytes (CTL), natural  killer (NK) cells; 
lymphokine activated killer (LAK) cells and BCG-activated killer cells (BAK). BAK cells are 
similar to NK and LAK cells but have some differences, as the effects are believed to last 
longer than those of the other killer cells.78 The production of effector cells is stimulated by 
cytokines.  The cytokines,  especially  IFN-γ,  also induce the expression and upregulation of 
MHC class II and intracellular adhesion molecular 1 by the tumour cells. This helps in the 
recognition and destruction of the tumour by the effector cells.77
The peak immune response is usually noted around 6–24 hours after instillation and 
there is a cumulative increase in response up to the fifth or sixth cycle. The response slowly 
continues to wane over a period but the exact duration of response is not clear as cytokine-
producing infiltrates have been identified up to 21 months after treatment.81 This is the rationale 
for maintenance therapy.
Maintenance therapy is necessary for optimal efficacy
In the EORTC meta-analysis,51 only patients receiving maintenance BCG benefited. In 
the four trials where no maintenance was given, no reduction of progression was observed. In 
the 20 trials in which some form of BCG maintenance was given, a reduction of 37% in the risk 
of progression was observed (p = 0.00004). The metaanalysis was unable to determine which 
BCG  maintenance  schedule  was  the  most  effective.  In  their  metaanalysis,  Bohle  et  al. 
concluded that at least 1 year of maintenance BCG was required to show the superiority of 
BCG over mitomycin C in preventing recurrence.
BCG toxicity
Assuming that maintenance therapy is necessary for optimal efficacy, the issue of BCG 
toxicity becomes more relevant. Due to the more pronounced side-effects of BCG compared to 
intravesical chemotherapy, reluctance still exists about BCG use. Early publications reporting 
deaths due to BCG sepsis and indicating that BCG induced cystitis occurs in up to 90% of 
patients have strongly compromised the use of BCG.
However, with increased experience in applying BCG, the side-effects now appear to be 
less  prominent  and  few,  if  any,  deaths  due  to  BCG therapy  have  been  reported  in  recent 
literature. Serious side effects are encountered in less than 5% of patients and can be effectively 
treated in virtually all cases51, 82 (level of evidence: 2).
The optimal schedule for BCG
Although some modifications have been tried, induction BCG instillations are classically 
given according to the empirical 6-weekly induction schedule introduced by Morales 30 years 
ago. Maintenance therapy involves continuous treatment with BCG after successful induction 
therapy.  However,  there  is  no  standard  maintenance  therapy  schedule,  many  different 
maintenance schedules have been used, ranging from a total of 10 instillations given in 18 
weeks, to 30 instillations given over 3 years.83 The optimal number of induction instillations 
and the optimal frequency and duration of maintenance instillations remain unknown. The main 
concern regarding maintenance therapy has been the side effects associated with BCG 
The optimal dose of BCG
To reduce BCG toxicity, a number of authors have proposed one-third and one-quarter 
dose instillations of BCG. Comparing one-third dose to full-dose BCG in 500 patients,  the 
Spanish Oncology Group (CUETO) found no overall difference in efficacy. However, there 
was a suggestion that a full dose of BCG may be more effective in multifocal disease84 (level of 
evidence: 2). Although fewer patients reported toxicity with the reduced dose, the incidence of 
severe systemic toxicity was similar in the standard and reduced dose groups. Further research 
is  required  to  determine the  optimal  dose  of  BCG, both  for  induction instillations  and for 
maintenance. Kelley et al measured the CFU in each batch of BCG vials and noted that the 
batch with 6 × 106 CFU had a higher recurrence rate compared to another batch with 300 
billion CFU.
Treatment of failures of instillation therapy
Failure of adjuvant intravesical therapy is poorly defined. While progression to muscle-
invasive disease is the trigger for cystectomy in most cases, there are other features that may 
indicate the failure of intravesical instillations.
The treatment can be considered to fail when 
• Higher grade or T category or carcinoma in situ (Tis) appear during therapy. 
• If a recurrence (even of the same grade and T category) is present at both 3 months 
and 6 months, the therapy can also be considered to be a failure because only a few 
patients will respond to further intravesical therapy (51) (level of evidence: 3). 
• A recurrence  at  3  months  is  not  considered  to  be  a  failure  because  additional 
treatment provokes complete remission in about one-fifth of patients.
Changing from BCG to chemotherapy can give further remissions in selected cases. 
The time to response to intravesical therapy is not defined. Although it is known that 
BCG immunotherapy needs some time to evoke an immune response, it is unknown how long 
the clinician may wait for a response without jeopardizing the patient. Delaying cystectomy 
might lead to progression, metastases and death from bladder cancer. Patients with no response 
to BCG at 6 months after starting BCG should be offered radical cystectomy. Furthermore, the 
appearance of  new superficial  tumours  every  3 months,  the  consequent  TUR,  the  ongoing 
intravesical instillations, etc., may lead to a bladder of such low quality in terms of capacity, 
urge, pain, etc., that, in selected cases, a patient should undergo a cystectomy.
Follow-up of patients with TaT1 bladder tumours51
Recommendations for follow-up cystoscopy
• Patients with low-risk (TaG1) tumours (50% of all patients) should have a cystoscopy at 3 
months. If negative, the following cystoscopy is advised at 9 months and consequently yearly 
for 5 years
High-risk  patients  (15%  of  all  patients)  should  have  a  cystoscopy  at  3  months.  If 
negative, the following cystoscopies should be repeated every 3 months for a period of 2 years, 
every 4 months in the third year, every 6 months thereafter until 5 years, and yearly thereafter. 
A yearly IVU should be recommended
Patients with intermediate-risk factors (about one-third of all patients) should have an in-
between follow-up scheme, adapted according to personal and subjective factors.
Prophylactic treatment 
One  of  the  main  aims  of  treating  patients  with  intravesical  BCG  is  to  reduce  the 
recurrence and progression rate.
CIS
CIS in the bladder is a high-grade noninvasive disease with a progression rate of more 
than 50%. The complete response rate to intravesical BCG varies between 60% and 79% based 
on 41 studies with a total of 1,496 patients.
Lamm et al showed a complete response rate of 70% with a median duration of response 
of 39 months when BCG was used in the treatment of CIS; 45% of patients were disease free 
after 5 years and 64% of patients who had a complete response remained disease-free for 5 
years or more.
In another South West Oncology Group (SWOG) study, an additional 3-week course of 
BCG at 3 months resulted in a further 25% increase in the complete response rate at 6 months, 
and  with  further  maintenance  every  6  months  for  3  years,  there  was  an  estimated  5-year 
disease-free rate of more than 75%. With these impressive results, BCG has replaced radical 
cystectomy as the treatment of choice in the management of patients with CIS.
Residual disease
Eradication of residual disease is another indication for using intravesical BCG. This 
group of patients forms a very small proportion of patients who have BCG treatment and are 
usually patients who are not fit to undergo endoscopic resection or patients with very extensive 
Ta or T1 disease. The response rate is usually around 60% to 70%.
BCG vs. intravesical chemotherapy
BCG has been shown to be superior to many of the intravesical chemotherapy agents 
used. However, very few studies have shown it to be better than mitomycin C (MMC) in terms 
of  recurrence.  One of the  main reasons for  this  is  that  in  many of  the studies,  patients  of 
varying risk groups were analysed together. 
In the Cochrane review, when BCG was compared to mitomycin C, it was noted that 
tumour recurrence was significantly reduced with BCG only in the subgroup of patients at high 
risk of tumour recurrence. However, there was no difference in terms of disease progression or 
survival. However, others have shown a survival benefit with BCG treatment. 
Herr et al in their  review reported that in high risk and recurrent superficial bladder 
cancer, patients treated with intravesical BCG had superior disease-free survival. Lamm et al 
also showed that maintenance BCG improved disease-free survival. 
SIDE EFFECTS 
While  generally  well-tolerated,  both  local  and systemic infectious  complications  can 
arise. The primary side effects of BCG are increased urinary frequency, dysuria, hematuria, and 
flu-like symptoms. Systemic symptoms can include arthralgia/arthritis, rash, fatigue, fever, and 
systemic BCG infection.
PATHOGENESIS OF TOXICITIES — 
The mechanism by which BCG leads to the development of infectious complications is 
not adequately understood. Its mechanism of action as an immunotherapeutic agent in cancer is 
not  fully  known but recent evidence suggests  that  elaboration of a  particular helper  T cell 
cytokine profile known as the "Th1 response" is an integral part of its mechanism. 85
Considerable debate exists in the literature about whether infectious complications due 
to BCG represent a hypersensitivity response or actual ongoing infection. The hypersensitivity 
hypothesis gained early credence based upon the presence of granulomas and the absence of 
recoverable  organisms.86,  87 A  response  to  corticosteroids,  administered  along  with 
antituberculous drugs, has also supported the notion of a hypersensitivity response.
In contrast, other case reports have demonstrated viable organisms in a variety of tissues, 
including lung, psoas abscess contents, mycotic aneurysm, bone marrow, and vitreous fluid. 
The  fastidious  growth  nature  of  BCG  in  culture  and  a  doubling  time  of  24  to  48  hours 
contribute to the difficulty in its isolation. M. bovis has also been demonstrated by PCR in 
some cases, although in other reports these studies have been negative.
Both viewpoints about the pathogenesis of complications due to BCG have merit and 
both probably play a role in the manifestations of disseminated infection. Organisms are most 
likely to gain access to lymphatics and blood through disruption of uroepithelial cells and, as 
with other mycobacterial infections, disseminate to a variety of sites. Manifestations at these 
distant  sites  may  reflect  initial  dissemination  or  even  reactivation  of  infection  following 
alteration in the immune status of the host, hypersensitivity responses,  or a combination of 
both. 
EPIDEMIOLOGY — severe  adverse  events  due  to  local  instillation  of  BCG  are 
uncommon. In a retrospective analysis of 2602 patients reported in 1989, the overall rate of 
serious complications was less than five percent. The most common complication was fever 
>103ºF in 2.9 percent followed in decreasing frequency by: 
Significant  hematuria  (1%),  Granulomatous  prostatitis  (0.9%)  Pneumonitis  and/or 
hepatitis (0.7%) Arthralgia (0.5%) Epididymitis (0.4%) Sepsis (0.4%) Rash (0.3%) Ureteral 
obstruction (0.3%) Contracted bladder (0.2%) Renal abscess (0.1 %) Cytopenia (0.1%). No 
differences  in  the  incidence  of  complications  were  observed  comparing  different  BCG 
preparations or doses.88 A Cochrane review identified six randomized trials of intravesical BCG 
including  585 patients;  local  complications  included urinary  frequency,  cystitis,  fever,  and 
hematuria in 71,  67,  25,  and 23 percent,  respectively.89 No cases of  BCG sepsis  or deaths 
occurred in this review.
There are conflicting data on the safety of steroids in patients treated with BCG. In one 
series  of  24  patients  who  had  concomitant  treatment  with  steroids  or  were  immuno 
compromised the incidence of side effects was comparable to that of patients without evidence 
of immuno suppression.90 In contrast, a fatal case of BCG reactivation and sepsis three years 
after uneventful BCG treatment for bladder cancer was documented following several months 
of oral prednisone therapy.91
Systemic sepsis and even death can also develop early following local instillation of 
BCG. During the initial clinical experience with BCG as an intravesical agent, most cases of 
sepsis  could  be  traced back to  recognized errors  in  BCG administration  such as  traumatic 
catheterization,  administration  too  early  after  transurethral  surgery,  or  instillation  during  a 
concomitant UTI.  All these conditions result  in physical disruptions in the urothelial  blood 
barrier. Nowadays, sepsis has been estimated to occur in approximately one in every 15,000 
patients treated with intravesical BCG.88
LOCAL COMPLICATIONS — Symptoms of  bladder  irritation,  such  as  dysuria  and 
frequency, develop in the majority of patients within two to four hours of BCG instillation; a 
low grade fever and malaise may accompany these symptoms, especially in patients who have 
received  prior  intravesical  instillations.86 Such  manifestations  generally  resolve  within  48 
hours.
Infection can also spread locally to  involve structures within the genitourinary tract. 
Such infections include granulomatous prostatitis, epididymitis, ureteral obstruction, bladder 
contracture and renal abscess.92,  93 Granulomatous prostatitis may be quite common although 
symptomatic  disease  is  not.  In  one  series  of  12  patients  undergoing  cystoprostatectomy 
following BCG instillation, nine had evidence of granulomatous prostatitis.94 
Symptoms from BCG infection of any of these structures cannot be distinguished from 
infection due to other organisms. This is particularly problematic as up to 20 percent of patients 
receiving  intravesical  BCG  develop  a  conventional  bacterial  UTI  at  some  point  during 
treatment.95 Occurrence in proximity to local instillation of BCG can be helpful, but cases of 
epididymo-orchitis arising years after the BCG therapy have been described.96 Thus, a level of 
clinical suspicion must be maintained once this treatment has been administered. In one report 
of eight cases with a review of the literature, the authors describe both early and late (>1 year) 
presentations of BCG infection; the late disease involved local granulomatous infection in the 
genitourinary tract usually with positive cultures for M. bovis.97
SYSTEMIC  COMPLICATIONS — The  most  serious  complications  of  BCG 
intravesical instillation relate to disseminated infection. 
Sepsis — A classic sepsis syndrome can occur, complete with fever, rigors, hypotension, 
disseminated  intravascular  coagulation,  and  respiratory  failure.93 These  manifestations  are 
probably due to high levels of cytokines released directly into the bloodstream as part of the 
hypersensitivity response (so called cytokine storm).98 This rare event typically develops soon 
after  the  BCG  instillation.  Delayed  cases  have  been  reported  years  after  an  apparently 
uncomplicated  treatment;  the  administration  of  systemic  corticosteroids  may  have  caused 
reactivation of a dormant focus in one of these latter cases.91
Granulomatous hepatitis — Granulomatous hepatitis can rarely arise as either an early or 
late  complication  of  BCG  intravesical  instillations.  Patients  with  granulomatous  hepatitis 
present with symptoms and signs of hepatitis, including fever, anorexia, and jaundice. Non-
caseating  granulomas  are  found  on  liver  biopsy;  eosinophils  can  also  be  seen  in  these 
specimens.86 Three  cases  have  been  reported  in  which  renal  insufficiency  accompanied 
granulomatous hepatitis; epithelioid granulomas were found on renal biopsy in two of these 
patients.99 A  progressive  mycotic  abdominal  aneurysm  was  also  noted  in  one  case  of 
granulomatous hepatitis, which occurred a year after the last BCG instillation.100 
Pneumonitis — A miliary nodular or interstitial pattern on routine chest radiography and 
CT  scanning  develops  in  some  patients  with  disseminated  BCG  infection,  most  often  in 
association with sepsis.87 Dyspnea,  accompanied by fever  and malaise,  has been described. 
Progression to respiratory compromise can occur.
Osteomyelitis — Osteomyelitis  is  another  rare  complication  of  disseminated  BCG 
infection. The majority of the handful of reported cases involves the spine, 101, 102 presumably 
due to spread from the urinary tract through Batson's plexus. 
Other — Other sites of infection may be caused by BCG. 
• A fever of unknown origin 
• Granulomas in bone marrow. 
• Mycotic aneurysms.
• Endophthalmitis. 
DIAGNOSIS — Specimens should be obtained for staining for acid-fast bacilli, culture, 
and PCR testing for  mycobacterial  DNA in any patient  with suspected disseminated BCG 
infection, even though all of these procedures can be negative in some cases85,86. 
Empiric therapy may be instituted when the clinical suspicion is high. Despite concerns 
about cases in which M. bovis  cannot be demonstrated,  organisms have been recovered or 
demonstrated by PCR in an increasing proportion of cases. 
The presence of breaks in the urogenital epithelium is known to be a risk factor for the 
development of disseminated infection.87 Thus, patients with difficult bladder catheterizations, 
preexisting  cystitis,  or  persistent  gross  hematuria  following  transurethral  resection  of  the 
bladder  tumor (TURBT) should have BCG instillation deferred for  a  minimum interval  of 
several weeks.
Reduction of BCG-related local side effects and fever can be achieved by BCG dose 
reduction to one-half to one-fourth of the typical dose. 
While many studies have shown that  BCG regimens using lower doses have similar 
efficacy,  at  least  one  trial  showed a  significantly  reduced cancer  response  rate.103 For  this 
reason titration of the BCG dose to a level where symptoms are acceptable is becoming a 
preferred alternative to automatic dose reduction. Other regimen modifications that improve 
BCG tolerance include reducing the dwell time to 30 minutes or applying treatments on an 
every other week schedule as needed.104, 105
Intravesical  BCG is  an effective  and well  established immunotherapy for  superficial 
TCC of the bladder. However, the optimum dose and schedule of treatment is yet to be defined. 
The other important aspect that needs to be established is the prognostic or predictive factors of 
treatment response. This is important for selecting patients who will benefit from the treatment 
to  avoid  unnecessary  radical  treatment  and  toxicities,  at  the  same  time  to  identify 
nonresponders early on so that they can be offered alternative treatment without compromising 
their prognosis. The BCG therapy is associated with toxicities but most are mild and resolve 
after discontinuation & symptomatic treatment. The life threatening complications may occur 
with such therapy, so high clinical suspicion and prompt treatment may be helpful. Currently 
the studies testing lower doses have shown lesser toxicities with equal efficacy, such therapies 
need to be explored further, to reduce complications and improve compliance.
RESULTS
A  total  of  56  patients  diagnosed  as  superficial  bladder  cancers  were  treated  with 
intravesical BCG from March 2005 to September 2007. 
Patient characteristics
The age of the patients ranged from 25 yrs to 86 years, with maximum 35.7% presenting 
in the seventh decade and 25% in the sixth decade, 25% were younger than 50 years and 14.3% 
were above 80 years, age group distribution is shown in Chart 1. 
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There were 47 males (83%) and 9 females in this study as shown in Chart 2.
Chart 2 : GENDER DISTRIBUTION 
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Only  12.5% were  from city,  44.6% from the  various  parts  of  the  state,  43% from 
neighbouring states  and 37.5% of patients  were illiterates  and 41% of  total  patients  were 
labourers. On asking about addictions, 24(43%) patients were smokers and 13% took alcohol 
socially. 
All patients were in good physical health of which 33(60%) patients had comorbidities 
of  which  only  25(75%)  were  on  medication.  36%  patients  were  Hypertensive  with  16% 
patients also having Ischemic Heart Disease, 26% were diabetics and additional 12.5% having 
other comorbidities which included hypothyroidism and bronchial asthma. 
Presentation 
The most common presentation was Painless hematuria 46(82%) either alone or with 
dysuria 7(12.5%), other presentations included Pain during voiding & flank pain in 3 patients, 2 
patients had increased frequency, whereas 1 patient had Pyuria and one had Retention of urine.
Patients had symptom duration ranging from less than 1 month to 24 months before 
seeking any medical attention. 3 patients had symptoms for 3, 8 & 12 years & were diagnosed 
previously & had undergone TURBT as previous therapy. Mean duration of symptoms was 3.6 
months (range < 1 to 120 months)
Patients were grouped according to the risk groups as per AJCC staging as shown in 
table 1.
Table 1: Risk group stratification according to stage & grade.
RISK GROUP No of pts % SUB GROUPS
LOW RISK 2 3.6% TaG1
INTERMEDIATE 34 58.9% T1G1, T1G2, 
TaG2
HIGH 17 32.1% TaG3, T1G3
DYSPLASIA 3 5.4% DYS
Only 2 patients presented with low stage low grade disease, 34 (59%) had intermediate 
risk group, 31% were in high risk advanced stage disease and while 5.4% had dysplasia. 
The time gap between the last TURBT and BCG administration was less than 2 weeks in 
7(12.5%) patients only and majority received after 2 weeks of intervention.
Patients undergoing and completing the therapy while on weekly and monthly schedules 
is as per shown in table 2.
Table 2: Therapy completion rates
WEEKLY (n 56) MONTHLY (48)
Completed 48 (85%) 28 (58%)
Defaulted 4 (7%) 6 (12.5%)
stopped 2(3.5%) 6 (12.5%)
On treatment 2 (3.5%) 8 (16.6%)
During therapy 38 (65.4%) patients experienced some form of toxicity, of which 60% 
experienced during weekly schedule, 40% on monthly and 15.7% experienced both on weekly 
and monthly schedules.
The common side effects experienced by the patients were dysuria, hematuria, UTI, pain 
on and after administration of BCG, cystitis and are as depicted in the chart 3.
Chart 3: Incidence Of Common Toxicities
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Most  patients  experienced  toxicities  during  weekly  instillations  as  compared  to  the 
monthly administration, the timing of toxicity with respect to BCG instillation is as shown in 
chat 4
Chat 4: Toxicity with respect to timing of BCG administration
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The most common systemic symptoms included fatigue & bodyache. Others symptoms 
were arthralgia which was present in 2 patients. 
One patient had ARF requiring dialysis, which recovered with supportive care and is 
doing well. 
In our study another 2 patients had deranged blood sugars, first patient had no history of 
Diabetes Mellitus, he also had significant weight loss > 10 kgs and constitutional symptoms. 
Another patient a known diabetic had deranged blood sugars which were however attributed to 
poor drug compliance. Both the patients recovered fully after completion of the treatment. 
A = During weekly
B = Post weekly
C = During monthly
D = After monthly
In patients developing UTI most common organism isolated was Klebsiella followed by 
E. fecalis. Stricture of urethera and meatal stenosis usually more common following instillation 
after procedural trauma, though there were no procedural complications in this study, Uretheral 
stricture or Meatal stenosis was noted in 6 patients. 
Cough and upper respiratory tract infection like features were present in 12 patients. One 
patient had presented with symptoms suggestive of disseminated disease with predominantly 
lung symptoms, systemic ‘BCGosis’ was thought but all the infectious work up was negative. 
No anti tubercular treatment was given and patient responded after stopping the treatment and 
with supportive care. Another  patient had upper respiratory tract infection with fever however 
work up was negative for any systemic BCG infection, the patient recovered with supportive 
therapy
One  patient  each  had  documented  Granulomatous  prostatitis  and  epididymo-orchitis 
while on follow up.
On follow up or during therapy 15 (26.7%) had recurrence, the intervention done and 
outcome & status of which is as per the table 3. 
Table 3: Recurrence, intervention and status
RECURRENCE (n 15 PATIENTS)
Intervention No of patients Status
TURBT (n  = 7) 6 NAD
1 Expired (defaulted)
CYSTECTOMY 3 NAD
Not Willing for Rx 2 LFU (defaulted)
RT 1 LFU (defaulted)
On evaluation 2 On W/U
At the time of analysis of this study 30 patients were without any symptoms of disease, 
10 were still on maintenance treatment, 9 had defaulted out of which 1 patient had died of 
progressive disease, 3 patients underwent Radical cystectomy, 2 are on re-BCG and 2 patients 
are on further evaluation for recurrence.
DISCUSSION
Since the initial report in 1976 that intravesical instillation of BCG reduced the rate of 
recurrence of superficial transitional cell carcinoma, the superiority to chemotherapy and the 
safety of BCG immunotherapy have been repeatedly confirmed The mechanism of action is 
thought to be BCG-mediated modulation of the immune response in the bladder, resulting in 
inflammation and subsequent elimination of the tumor. However inoculating a viable infectious 
agent into the bladder raises the potential risk of local or generalized infection, just as has been 
described following intradermal BCG vaccination for prevention of tuberculosis 
A  review  of  literature  regarding  the  complications  reported  with  the  treatment  of 
superficial bladder cancer with intravesical BCG was done including the Pubmed and Internet 
resources.
As opposed to treatment efficacy comparisons available, comparing complications rates 
from different  studies  was  problematic  as  most  studies  have not  particularly  looked at  the 
complications and study variables are not uniform.
In the Cochrane review of 2007 for intravesical BCG, the mean age was 64 in the TUR 
plus BCG group, with the male to female ratios of 3.5. The mean percentage of patients with 
Ta  and  T1  tumours  were  41  and  59% (TUR plus  BCG).109 In  our  study  the  mea  age  at 
presentation was 57 years and male to female ratio was 5.2 :1. The % of Ta & T1 tumours was 
41 & 52% respectively.
In the Cochrane review of intravesical therapy complications (2007) the main toxicities 
associated  with  BCG  were  cystitis  (67%),  haematuria  (23%),  fever  (25%)  and  urinary 
frequency (71%). No BCG sepsis or deaths were reported.109
In  review of  literature in  relation to  complications of  BCG by American Urological 
Association reported incidence of Hematuria (29%), LUTS (57 – 71%), Urethral infections 
(4%), systemic symptoms (22 – 30%) and bladder contracture in 3% patients.106 The incidence 
of BCG side effects have been reported to be BCG cystitis in 57 – 91%, Hematuria (26 – 55%) 
and Fever (28 – 73%) in studies reported by Lamm, Morales, and Sasaki et al. 
In another Japanese study by Suzuki et al 107 the incidence of BCG- induced side effects 
was  more  than  80%,  but  major  side  effects  that  required  treatment  and  postponement  or 
discontinuation of BCG instillation occurred in 50% courses or less reported in 41.8%.
In  another  study  by  Gonzalez  et  al108 reported  symptoms  of  BCG  infection  after 
treatment with instilled BCG were Fever & malaise, Urinary symptoms (62%) Chills, Sweats, 
Weight loss, Shortness of breath (37.5%), Arthralgia/arthritis, Nausea/vomiting, testicular or 
prostatic mass (25%), Ascites (12.5%) 
BCG induced toxicities (Cochrane review 07) in comparison with our study109
Krege 
1990
Lamm 
1985
Melekos 
1990
Pagano 
1990
Pinsky 
1985
Yamamoto
1990
Mean 
(%)
Our 
study
cystitis 34 93 84 27 88 76 67 7
Haematuria 6 34 21 3 58 14 23 10
Fever 18 28 27 16 44 14 25 6
Frequency - 90 - - 51 - 71 2
Flu-like - 7 10 - 28 - 15 6
Nausea - 11 7 - 5 - 8 -
Malaise - 10 7 - 26 - 14 2
Prostatitis 5 1 1 2 2 - 3 1
Epididymitis 10 1 - 2 - - 6 1
Allergic 3 - - - 19 - 10 -
Contracted 
bladder
- 0 - 1 0 10 2 1
BCG-Sepsis - 0 - 0 0 - 0 0
Deaths 0 0 0 0 0 0 0 0
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In our study the most common symptom was UTI followed by Dysuria 
(24%), Hematuria occurred in 10% and cystitis occurred in 7% patients. The 
incidence  of  Cystitis  is  much  less  in  our  study  as  compared  to  the  other 
studies,  which is minimal as compared to studies in Cochrane review. The 
lowest incidence is in the study by Pagano et al (27%). The high incidence in 
the other studies is  probably due to overlapping symptoms of cystitis  with 
LUTS or probably may also be related to different strains of BCG vaccine 
used in different studies. Also in various studies there is no uniformity in the 
description of Cystitis. Also in our study we had UTI in 25% patients.
In our patients incidence of Hematuria was 10% which was also less as 
reported  in  the  Cochrane  review  (mean  23%)  and  other  studies.  In  a 
metaanalysis of 9 trials by Madhusudan P. Koya et al, incidence of hematuria 
was reported ranging from 1 to 9% of patients.111
Most  of  studies  have  not  looked  at  increased  frequency  or  allergic 
reactions & few studies have reported malaise and flu like symptoms. In our 
patients  only  2%  had  increased  frequency  as  compared  to  mean  71%  of 
patients which was looked into in only 2 of the studies. In our study no allergic 
reactions were noted. 
Arthralgia was present in 2 patients, in the literature arthritis is usually 
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regarded  as  a  rare  event  but  Andreas  Bohle  et  al in  their  study  “QOL 
assessment  during  intravesical  therapy” observed that  a  no  of  patients  had 
complained about arthralgia/ arthritis.112
In our study one patient had ARF requiring Dialysis, the renal functions 
returned to normal after discontinuation of therapy. On literature review a case 
report  describing  similar  toxicity  (ARF)  was  reported  with  uneventful 
recovery of the patient.  It  was found that  although renal complications are 
uncommon, several cases of interstitial nephritis (with or without granulomas) 
and  mesangial  glomerulonephritis  have  been  reported  and  underlying 
interstitial nephritis may be the underlying factor.113  the other toxicities such 
as  Granulomatous  prostatitis,  Epididymo-orchitis,  bladder  contracture  are 
comparable as reported in the metaanalysis. In our patient 10% had meatal or 
ureteral  stenosis,  though described  in  the  literature,  the  incidence  in  other 
studies is not known. 
In our patient group only 1 patient had significant weight loss (>10kgs) 
&  11(19.6%)  had  systemic  symptoms  as  compared  to  37.5%  patients  as 
reported by Gonzalez et al.108
In our study there were no systemic BCG infections and no death was 
reported  while  on  treatment,  as  shown  in  other  studies,  though  anecdotal 
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reports are published.
Patients  usually  have  overlapping  symptom  complexes  and 
differentiating  predominant  symptoms  from  others  may  help  explain  the 
differences in reported toxicities. Also there is no uniformity in describing the 
various  symptoms  resulting  in  wide  variation  in  incidences  of  various 
toxicities.
In the literature the toxicities associated with BCG are reported in up to 
95% of patients110 but most are transient and self limiting requiring no specific 
intervention.
In our study 38 (68%) patients had some form of toxicity out of which 8 
(14%) had significant toxicity  requiring therapy to be stopped.  Whereas in 
SWOG trial 25% patients and Grade 3 toxicity or above and only 16% patients 
were  able  to  complete  planned  treatment.  In  our  study  85%  completed 
induction therapy and 58% completed maintenance therapy and 18% are still 
on treatment. In another Polish study 7% of patients had grade III toxicity and 
required cessation of therapy.114 
In our study statistically no significant association was found when the 
toxicity  group was  compared  with  various  variables  like  stage  distribution 
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with toxicity (p = 0.6), toxicity with comorbidities(as per chart 5, p = 0.6), 
toxicity with addictions (smoking: p = 0.06; alcohol, p = 0.9), toxicity with 
age group,  toxicity  with time gap between TURBT & intravesical  therapy, 
toxicity and relation with comorbidities or toxicity with recurrence rates (p = 
0.8). 
Chart 5 Relation of Comorbidity Group with Toxicity
COMORBOIDTY VS TOXICITY
8
10
25
13
PRESENT
ABSENT
CO
 M
O
RB
ID
IT
Y 
TOXICITY NO YES
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CONCLUSIONS
1. Intravesical BCG is an effective and well established immunotherapy 
for superficial TCC of the bladder.  However,  the optimum dose and 
schedule of treatment is yet to be defined.
2. BCG doses were well tolerated and the patient compliance was good 
with 70% of  the  patients  completing  the  therapy and 17  % still  on 
therapy.
3. The common toxicities reported were dysuria, hematuria, cystitis, UTI 
and systemic symptoms. Incidences of which are comparable to those 
reported in the literature. 
4. Majority  of  toxicities  were  mild  and  self  limiting  requiring  no 
intervention.  68%  patients  experienced  some  form  of  complications 
however  14%  had  significant  toxicities  requiring  treatment  to  be 
stopped. There were no BCG sepsis and no deaths were reported due to 
the therapy.
5. In our study no statistically significant factors or subgroups were found 
to be related to the development of side effects.
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6. There  is  need  for  larger  uniform  multicentric  studies  looking  at 
tolerance and complications in our subset of patients as there are no 
reported studies addressing the issue from our country. Also the QOL 
issues needs to be addressed in such larger studies.
7. The role of low dose BCG vs. standard doses needs to be addressed as 
various recent studies report equal efficacy with less toxicity. 
8. Overall  intravesical BCG is well tolerated therapy that can be safely 
administered as day care treatment.
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PROFORMA
Name Age / Sex O/No  DOA
Address
EDUCATION
Presenting complaints
DURATION
Personal Hx 
Drug Hx
Family hx
Occupation
Prev intervention
Cystoscopy (baseline)
Diagnosis: T G
Urine (R/M)
Date of TURBT Date of starting BCG time gap
BCG weekly
1st 2nd 3rd 4th 5th 6th 
Delay
Cause
Intervention
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Cystoscopy
BCG monthly
1st 2nd 3rd 4th 5th 6th
Delay
Cause
Intervention
Side effects/ complications weekly monthly
Fever
Chills rigors
Pain
UTI
‘Bcg’ osis
Hematuria
Dysuria
Cystitis
Increased frequency
Systemic symp
Procedural
Others
Infections:  UTI/ systemic/ 
Culture report
Antibiotics
Timing of toxicities
Recurrence
If yes intervention & outcome
Last Follow up 
Status at last follow up
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